Cargando…
Milestones in the systemic treatment of lung cancer
Several milestones in the systemic treatment of lung cancer have been reached. Combination chemotherapy of small cell lung cancer was the first of these milestones. The establishment of palliative chemotherapy in patients with advanced non-small cell lung cancer and of adjuvant chemotherapy in patie...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Vienna
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5357246/ https://www.ncbi.nlm.nih.gov/pubmed/28367252 http://dx.doi.org/10.1007/s12254-017-0313-9 |
| _version_ | 1782515993922240512 |
|---|---|
| author | Pirker, Robert |
| author_facet | Pirker, Robert |
| author_sort | Pirker, Robert |
| collection | PubMed |
| description | Several milestones in the systemic treatment of lung cancer have been reached. Combination chemotherapy of small cell lung cancer was the first of these milestones. The establishment of palliative chemotherapy in patients with advanced non-small cell lung cancer and of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer was another important milestone. Targeted therapies with angiogenesis inhibitors, EGFR inhibitors, and ALK inhibitors also advanced treatment. The clinical introduction of immune checkpoint inhibitors was the latest milestone. |
| format | Online Article Text |
| id | pubmed-5357246 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2017 |
| publisher | Springer Vienna |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-53572462017-03-30 Milestones in the systemic treatment of lung cancer Pirker, Robert Memo Short Review Several milestones in the systemic treatment of lung cancer have been reached. Combination chemotherapy of small cell lung cancer was the first of these milestones. The establishment of palliative chemotherapy in patients with advanced non-small cell lung cancer and of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer was another important milestone. Targeted therapies with angiogenesis inhibitors, EGFR inhibitors, and ALK inhibitors also advanced treatment. The clinical introduction of immune checkpoint inhibitors was the latest milestone. Springer Vienna 2017-02-06 2017 /pmc/articles/PMC5357246/ /pubmed/28367252 http://dx.doi.org/10.1007/s12254-017-0313-9 Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
| spellingShingle | Short Review Pirker, Robert Milestones in the systemic treatment of lung cancer |
| title | Milestones in the systemic treatment of lung cancer |
| title_full | Milestones in the systemic treatment of lung cancer |
| title_fullStr | Milestones in the systemic treatment of lung cancer |
| title_full_unstemmed | Milestones in the systemic treatment of lung cancer |
| title_short | Milestones in the systemic treatment of lung cancer |
| title_sort | milestones in the systemic treatment of lung cancer |
| topic | Short Review |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5357246/ https://www.ncbi.nlm.nih.gov/pubmed/28367252 http://dx.doi.org/10.1007/s12254-017-0313-9 |
| work_keys_str_mv | AT pirkerrobert milestonesinthesystemictreatmentoflungcancer |